Related Experiment Video
Updated: Sep 21, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis
Tatsuyuki Hayashi1, Izumi Yamaguchi, Hiroki Saitoh
1Division of Internal Medicine, Tokyo Metropolitan Police Hospital, Tokyo.
Abstract:
A 64-year-old Japanese man suffering from IgD lambda myeloma and renal failure requiring chronic hemodialysis was treated with thalidomide. Serum IgD concentration was 4,050 mg/dl and myeloma cells constituted 95.6% of nucleated cells in bone marrow at the start of treatment. These parameters improved markedly to 1,590 mg/dl and 22.0%, respectively, in the 4 months immediately prior to his death due to pneumonia. Thalidomide caused peripheral neuropathy and constipation at a dose of 100 mg daily in the first week of treatment, but adverse effects resolved upon dose reduction. Thalidomide represents a valid therapeutic option for some myeloma patients receiving hemodialysis.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Therapeutic Drug Monitoring: Affecting Factors
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Hemodialysis III: Nursing Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Chronic Kidney Disease IV: Nursing Management
